Peptide receptor radionuclide therapy (PRRT) with 90Y-DOTATOC or 177Lu-DOTATATE has demonstrated its efficacy in the treatment of neuroendocrine- and somatostatin-receptor expressing tumours . Several clinical trials have confirmed that adverse effects are represented by possible renal impairment and low but not absent haematological toxicity

Secondary acute myeloid leukaemia after peptide receptor radionuclide therapy

Paganelli, Giovanni
Penultimo
;
2012

Abstract

Peptide receptor radionuclide therapy (PRRT) with 90Y-DOTATOC or 177Lu-DOTATATE has demonstrated its efficacy in the treatment of neuroendocrine- and somatostatin-receptor expressing tumours . Several clinical trials have confirmed that adverse effects are represented by possible renal impairment and low but not absent haematological toxicity
2012
Piccin, Andrea; Grana, Chiara Maria; Negri, Giovanni; Pusceddu, Irene; Paganelli, Giovanni; Cortelazzo, Sergio
File in questo prodotto:
File Dimensione Formato  
piccin2011.pdf

accesso aperto

Tipologia: Full text (versione editoriale)
Licenza: Creative commons
Dimensione 62.17 kB
Formato Adobe PDF
62.17 kB Adobe PDF Visualizza/Apri

I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11392/2378297
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 2
social impact